Is NFX or CLBX more profitable?

Cellbxhealth's return on equity of 0.00% beat Nuformix's return on equity. Company Net Margins Return on Equity Return on Assets Nuformix N/A -83.53% -17.20% Cellbxhealth N/A N/A N/A

Is NFX or APTA more profitable?

Nuformix has a net margin of 0.00% compared to Aptamer Group's net margin of -178.52%. Nuformix's return on equity of -83.53% beat Aptamer Group's return on equity. Company Net Margins Return on Equity Return on Assets Nuformix N/A -83.53% -17.20% Aptamer Group -178.52% -135.35% -44.96%

Is NFX or FAB more profitable?

Nuformix has a net margin of 0.00% compared to Fusion Antibodies' net margin of -91.92%. Nuformix's return on equity of -83.53% beat Fusion Antibodies' return on equity. Company Net Margins Return on Equity Return on Assets Nuformix N/A -83.53% -17.20% Fusion Antibodies -91.92% -210.32% -63.78%

Is NFX or RLM more profitable?

Realm Therapeutics' return on equity of 0.00% beat Nuformix's return on equity. Company Net Margins Return on Equity Return on Assets Nuformix N/A -83.53% -17.20% Realm Therapeutics N/A N/A N/A

Nuformix (NFX) Competitors

GBX 0.18 +0.02 (+13.21%)

As of 12:12 PM Eastern

Compare

NFX vs. CLBX, APTA, FAB, RLM, and NSCI

Should you buy Nuformix stock or one of its competitors? MarketBeat compares Nuformix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nuformix include Cellbxhealth (CLBX), Aptamer Group (APTA), Fusion Antibodies (FAB), Realm Therapeutics (RLM), and NetScientific (NSCI). These companies are all part of the "biotechnology" industry.

How does Nuformix compare to Cellbxhealth?

Nuformix (LON:NFX) and Cellbxhealth (LON:CLBX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

Cellbxhealth's return on equity of 0.00% beat Nuformix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuformix	N/A	-83.53%	-17.20%
Cellbxhealth	N/A	N/A	N/A

0.1% of Nuformix shares are held by institutional investors. Comparatively, 0.4% of Cellbxhealth shares are held by institutional investors. 7.5% of Nuformix shares are held by insiders. Comparatively, 1.2% of Cellbxhealth shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Cellbxhealth had 1 more articles in the media than Nuformix. MarketBeat recorded 1 mentions for Cellbxhealth and 0 mentions for Nuformix. Cellbxhealth's average media sentiment score of 1.38 beat Nuformix's score of 0.00 indicating that Cellbxhealth is being referred to more favorably in the news media.

Company	Overall Sentiment
Nuformix	Neutral
Cellbxhealth	Positive

Cellbxhealth has higher revenue and earnings than Nuformix. Nuformix is trading at a lower price-to-earnings ratio than Cellbxhealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuformix	N/A	N/A	-£383.40K	-£0.03	N/A
Cellbxhealth	£1.15M	13.22	N/A	-£5.51	N/A

Summary

Cellbxhealth beats Nuformix on 7 of the 9 factors compared between the two stocks.

How does Nuformix compare to Aptamer Group?

Nuformix (LON:NFX) and Aptamer Group (LON:APTA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

Nuformix has higher earnings, but lower revenue than Aptamer Group. Nuformix is trading at a lower price-to-earnings ratio than Aptamer Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuformix	N/A	N/A	-£383.40K	-£0.03	N/A
Aptamer Group	£1.38M	11.66	-£14.17M	-£0.11	N/A

Nuformix has a net margin of 0.00% compared to Aptamer Group's net margin of -178.52%. Nuformix's return on equity of -83.53% beat Aptamer Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuformix	N/A	-83.53%	-17.20%
Aptamer Group	-178.52%	-135.35%	-44.96%

Nuformix has a beta of 1.537, suggesting that its share price is 54% more volatile than the broader market. Comparatively, Aptamer Group has a beta of 0.899, suggesting that its share price is 10% less volatile than the broader market.

0.1% of Nuformix shares are held by institutional investors. Comparatively, 3.0% of Aptamer Group shares are held by institutional investors. 7.5% of Nuformix shares are held by insiders. Comparatively, 7.3% of Aptamer Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Nuformix's average media sentiment score of 0.00 equaled Aptamer Group'saverage media sentiment score.

Company	Overall Sentiment
Nuformix	Neutral
Aptamer Group	Neutral

Summary

Nuformix beats Aptamer Group on 7 of the 10 factors compared between the two stocks.

How does Nuformix compare to Fusion Antibodies?

Nuformix (LON:NFX) and Fusion Antibodies (LON:FAB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

In the previous week, Fusion Antibodies had 1 more articles in the media than Nuformix. MarketBeat recorded 1 mentions for Fusion Antibodies and 0 mentions for Nuformix. Fusion Antibodies' average media sentiment score of 1.69 beat Nuformix's score of 0.00 indicating that Fusion Antibodies is being referred to more favorably in the news media.

Company	Overall Sentiment
Nuformix	Neutral
Fusion Antibodies	Very Positive

0.1% of Nuformix shares are owned by institutional investors. Comparatively, 7.6% of Fusion Antibodies shares are owned by institutional investors. 7.5% of Nuformix shares are owned by insiders. Comparatively, 5.9% of Fusion Antibodies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Nuformix has a beta of 1.537, meaning that its stock price is 54% more volatile than the broader market. Comparatively, Fusion Antibodies has a beta of 1.224, meaning that its stock price is 22% more volatile than the broader market.

Nuformix has a net margin of 0.00% compared to Fusion Antibodies' net margin of -91.92%. Nuformix's return on equity of -83.53% beat Fusion Antibodies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuformix	N/A	-83.53%	-17.20%
Fusion Antibodies	-91.92%	-210.32%	-63.78%

Nuformix has higher earnings, but lower revenue than Fusion Antibodies. Fusion Antibodies is trading at a lower price-to-earnings ratio than Nuformix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuformix	N/A	N/A	-£383.40K	-£0.03	N/A
Fusion Antibodies	£1.60M	8.09	-£4.10M	-£1.50	N/A

Summary

Nuformix beats Fusion Antibodies on 8 of the 12 factors compared between the two stocks.

How does Nuformix compare to Realm Therapeutics?

Nuformix (LON:NFX) and Realm Therapeutics (LON:RLM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

In the previous week, Nuformix's average media sentiment score of 0.00 equaled Realm Therapeutics'average media sentiment score.

Company	Overall Sentiment
Nuformix	Neutral
Realm Therapeutics	Neutral

0.1% of Nuformix shares are owned by institutional investors. 7.5% of Nuformix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Realm Therapeutics has higher revenue and earnings than Nuformix. Nuformix is trading at a lower price-to-earnings ratio than Realm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuformix	N/A	N/A	-£383.40K	-£0.03	N/A
Realm Therapeutics	£501.92K	0.00	N/A	-£17.50	N/A

Realm Therapeutics' return on equity of 0.00% beat Nuformix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuformix	N/A	-83.53%	-17.20%
Realm Therapeutics	N/A	N/A	N/A

Summary

Realm Therapeutics beats Nuformix on 4 of the 7 factors compared between the two stocks.

How does Nuformix compare to NetScientific?

NetScientific (LON:NSCI) and Nuformix (LON:NFX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

14.7% of NetScientific shares are owned by institutional investors. Comparatively, 0.1% of Nuformix shares are owned by institutional investors. 42.4% of NetScientific shares are owned by insiders. Comparatively, 7.5% of Nuformix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

NetScientific has a beta of 1.67, suggesting that its stock price is 67% more volatile than the broader market. Comparatively, Nuformix has a beta of 1.537, suggesting that its stock price is 54% more volatile than the broader market.

Nuformix has a net margin of 0.00% compared to NetScientific's net margin of -182.91%. NetScientific's return on equity of -13.70% beat Nuformix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NetScientific	-182.91%	-13.70%	-9.42%
Nuformix	N/A	-83.53%	-17.20%

In the previous week, NetScientific's average media sentiment score of 0.00 equaled Nuformix'saverage media sentiment score.

Company	Overall Sentiment
NetScientific	Neutral
Nuformix	Neutral

Nuformix has lower revenue, but higher earnings than NetScientific. Nuformix is trading at a lower price-to-earnings ratio than NetScientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NetScientific	£1.45M	0.00	-£2.64M	-£0.11	N/A
Nuformix	N/A	N/A	-£383.40K	-£0.03	N/A

Summary

NetScientific beats Nuformix on 6 of the 10 factors compared between the two stocks.

Get Nuformix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NFX vs. The Competition

Export

Metric	Nuformix	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£4.70M	£444.71M	£6.81B	£2.79B
Dividend Yield	N/A	3.90%	2.67%	6.16%
P/E Ratio	-6.14	3.49	26.97	368.25
Price / Sales	N/A	6,249.84	518.57	84,392.87
Price / Cash	3.55	13.13	49.71	27.89
Price / Book	0.33	87.68	10.67	7.59
Net Income	-£383.40K	-£96.07M	£3.60B	£5.89B
7 Day Performance	7.78%	-0.59%	-0.37%	0.05%
1 Month Performance	-2.70%	1.23%	1.80%	-0.66%
1 Year Performance	N/A	60.49%	25.50%	62.48%

Nuformix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NFX Nuformix	N/A	GBX 0.18 +13.2%	N/A	+89.3%	£4.70M	N/A	N/A	3
CLBX Cellbxhealth	N/A	GBX 1.47 +6.5%	N/A	N/A	£16.65M	£1.35M	N/A	N/A	Earnings Report Gap Up
APTA Aptamer Group	N/A	GBX 0.47 -0.6%	N/A	+16.0%	£16.31M	£1.38M	N/A	37
FAB Fusion Antibodies	N/A	GBX 10.99 -0.1%	N/A	+23.6%	£13.76M	£1.60M	N/A	48	News Coverage
RLM Realm Therapeutics	N/A	N/A	N/A	N/A	£13.41M	£501.92K	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:NFX) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuformix (NFX) Competitors

NFX vs. CLBX, APTA, FAB, RLM, and NSCI

How does Nuformix compare to Cellbxhealth?

Summary

How does Nuformix compare to Aptamer Group?

Summary

How does Nuformix compare to Fusion Antibodies?

Summary

How does Nuformix compare to Realm Therapeutics?

Summary

How does Nuformix compare to NetScientific?

Summary

Media Sentiment Over Time

NFX vs. The Competition

Nuformix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuformix (NFX) Competitors

NFX vs. CLBX, APTA, FAB, RLM, and NSCI

How does Nuformix compare to Cellbxhealth?

Is NFX or CLBX more profitable?

Do institutionals and insiders have more ownership in NFX or CLBX?

Does the media favor NFX or CLBX?

Which has stronger earnings & valuation, NFX or CLBX?

Summary

How does Nuformix compare to Aptamer Group?

Which has preferable valuation and earnings, NFX or APTA?

Is NFX or APTA more profitable?

Which has more risk and volatility, NFX or APTA?

Do insiders and institutionals hold more shares of NFX or APTA?

Does the media refer more to NFX or APTA?

Summary

How does Nuformix compare to Fusion Antibodies?

Does the media prefer NFX or FAB?

Do institutionals & insiders hold more shares of NFX or FAB?

Which has more volatility and risk, NFX or FAB?

Is NFX or FAB more profitable?

Which has higher valuation and earnings, NFX or FAB?

Summary

How does Nuformix compare to Realm Therapeutics?

Does the media refer more to NFX or RLM?

Do insiders & institutionals hold more shares of NFX or RLM?

Which has better valuation & earnings, NFX or RLM?

Is NFX or RLM more profitable?

Summary

How does Nuformix compare to NetScientific?

Do insiders and institutionals believe in NSCI or NFX?

Which has more volatility & risk, NSCI or NFX?

Is NSCI or NFX more profitable?

Does the media favor NSCI or NFX?

Which has stronger earnings & valuation, NSCI or NFX?

Summary

Media Sentiment Over Time

NFX vs. The Competition

Nuformix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools